Short Interest in Cyclo Therapeutics, Inc. (NASDAQ:CYTH) Increases By 43.0%

Cyclo Therapeutics, Inc. (NASDAQ:CYTH) was the recipient of a large growth in short interest in the month of July. As of July 15th, there was short interest totalling 41,600 shares, a growth of 43.0% from the June 30th total of 29,100 shares. Based on an average daily volume of 33,900 shares, the short-interest ratio is currently 1.2 days. Approximately 0.3% of the shares of the company are sold short.

Cyclo Therapeutics Stock Up 2.6 %

NASDAQ:CYTH traded up $0.03 during trading hours on Monday, hitting $1.18. 1,434,730 shares of the stock traded hands, compared to its average volume of 81,103. The company has a market cap of $33.77 million, a price-to-earnings ratio of -1.18 and a beta of -0.33. Cyclo Therapeutics has a 1 year low of $0.89 and a 1 year high of $2.12. The stock has a 50 day moving average price of $1.25 and a 200 day moving average price of $1.45.

Cyclo Therapeutics (NASDAQ:CYTH) last announced its quarterly earnings data on Wednesday, May 15th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.05. The firm had revenue of $0.20 million for the quarter, compared to the consensus estimate of $0.44 million. Cyclo Therapeutics had a negative net margin of 1,720.76% and a negative return on equity of 2,741.89%. Equities analysts forecast that Cyclo Therapeutics will post -0.62 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Cyclo Therapeutics

An institutional investor recently bought a new position in Cyclo Therapeutics stock. Founders Fund V Management LLC bought a new stake in shares of Cyclo Therapeutics, Inc. (NASDAQ:CYTH) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 480,708 shares of the company’s stock, valued at approximately $764,000. Cyclo Therapeutics makes up approximately 80.8% of Founders Fund V Management LLC’s portfolio, making the stock its largest position. Founders Fund V Management LLC owned 2.11% of Cyclo Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 68.55% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on CYTH. Ascendiant Capital Markets assumed coverage on shares of Cyclo Therapeutics in a research note on Monday, April 22nd. They set a “buy” rating and a $2.60 price target on the stock. HC Wainwright reiterated a “buy” rating and set a $3.00 target price on shares of Cyclo Therapeutics in a research report on Friday, May 31st.

Cyclo Therapeutics Company Profile

Cyclo Therapeutics, Inc, a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease.